drugset
drugset / Trial / NCT05745207

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

NCT05745207 ↗

Phase 1 Completed 53 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindOther

Summary

The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.

Timeline

Start
2023-02-20
Primary completion
2024-01-18
Completion
2024-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject E2086 Unknown 1 mg Oral
Subject E2086 Unknown 2.5 mg Oral
Subject E2086 Unknown 5 mg Oral
Subject E2086 Unknown 10 mg Oral
Subject E2086 Unknown 25 mg Oral
Subject E2086 Unknown 50 mg Oral
Subject E2086 Unknown 100 mg Oral

Indications

No indication recorded.